Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis

Fan, Jie; Yang, Yifei; Yuan, Chunhui; Chen, Hao; Wang, Xinghuan

doi:10.1159/000430382

Cited by 58 publications

(61 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The numbers of CTCs were closely correlated with portal vein thrombosis, tumor infiltration, prognosis and Child-Pugh grade [61,64,69] . Most of the studies have shown that before liver resection or transplantation, tumor cells from the primary lesions were detached and threw into the blood being the early event of HCC metastases.…”

Section: Ctcsmentioning

confidence: 92%

“…Most of the studies have shown that before liver resection or transplantation, tumor cells from the primary lesions were detached and threw into the blood being the early event of HCC metastases. Fan et al [69,70] reported that the tumor recurrence after resection was associated with the number of CTCs detected, maybe because CTCs were still surviving into the blood [70][71][72] . However, the role of CTCs and HCC recurrence require further investigations.…”

Section: Ctcsmentioning

confidence: 99%

See 1 more Smart Citation

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Section: Ctcsmentioning

confidence: 92%

Section: Ctcsmentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

show abstract

“…CTCs have been reported in patients with HCC, but the characteristically low EpCAM cell surface expression in this tumor type has limited the utility of standard CTC measurements (12,13). To establish a high-throughput, bloodbased assay for HCC that would have broad applicability, we therefore adapted the microfluidic CTC-iChip isolation platform with a digital RNA-PCR readout combining liver-specific transcripts whose expression is retained in HCC.…”

Section: Significancementioning

confidence: 99%

An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma

Kalinich

Bhan

Kwan

et al. 2017

Proc. Natl. Acad. Sci. U.S.A.

137

146

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are shed into the bloodstream by invasive cancers, but the difficulty inherent in identifying these rare cells by microscopy has precluded their routine use in monitoring or screening for cancer. We recently described a high-throughput microfluidic CTC-iChip, which efficiently depletes hematopoietic cells from blood specimens and enriches for CTCs with well-preserved RNA. Application of RNA-based digital PCR to detect CTC-derived signatures may thus enable highly accurate tissue lineage-based cancer detection in blood specimens. As proof of principle, we examined hepatocellular carcinoma (HCC), a cancer that is derived from liver cells bearing a unique gene expression profile. After identifying a digital signature of 10 liver-specific transcripts, we used a cross-validated logistic regression model to identify the presence of HCC-derived CTCs in nine of 16 (56%) untreated patients with HCC versus one of 31 (3%) patients with nonmalignant liver disease at risk for developing HCC (P < 0.0001). Positive CTC scores declined in treated patients: Nine of 32 (28%) patients receiving therapy and only one of 15 (7%) patients who had undergone curative-intent ablation, surgery, or liver transplantation were positive. RNA-based digital CTC scoring was not correlated with the standard HCC serum protein marker alpha fetoprotein (P = 0.57). Modeling the sequential use of these two orthogonal markers for liver cancer screening in patients with high-risk cirrhosis generates positive and negative predictive values of 80% and 86%, respectively. Thus, digital RNA quantitation constitutes a sensitive and specific CTC readout, enabling high-throughput clinical applications, such as noninvasive screening for HCC in populations where viral hepatitis and cirrhosis are prevalent.circulating tumor cells | early cancer detection | hepatocellular carcinoma | blood biopsy | predictive modeling T he shedding by epithelial cancers of circulating tumor cells (CTCs) into the bloodstream underlies the blood-borne dissemination of cancer, although only a small fraction of CTCs gives rise to metastases (1). Enumeration and analysis of CTCs may thus enable noninvasive monitoring of advanced cancers, as well as early detection of invasive but localized tumors before they give rise to viable metastases. Recent advances in CTC isolation provide sensitive and high-throughput platforms to enrich for these rare tumor cells within blood specimens, but antibody staining and microscopic imaging of captured cancer cells remain a critical bottleneck limiting broad application of the technology (2). Classical CTC staining criteria include the presence of cell surface epithelial cell adhesion molecule (EpCAM) and cytoplasmic epithelial cytokeratins and the absence of the hematopoietic CD45 marker (3), but epithelial marker expression is highly variable and extensive imaging criteria must be applied to score immunofluorescent signals reliably from rare cancer cells surrounded by contaminating leukocytes (4). Emerging microfluidic C...

show abstract

“…These cells have recently been exploited for guiding clinical management, evaluating curative efficacy, predicting prognosis and monitoring tumor recurrence [7]. The CellSearch system is the only CTC detection technology approved by the FDA.…”

Section: Introductionmentioning

confidence: 99%

Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma

Liang

Sun

Wang

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circulating tumor cells (CTCs) are valuable in both basic research and clinical application for cancer management. In the current study, we evaluated the diagnostic value of CTCs in pancreatic ductal adenocarcinoma (PDAC). Methods: In total, 143 blood samples from 95 consecutively diagnosed PDAC patients and 48 healthy donors were collected. Combined data from immunostaining of CD45, DAPI and fluorescence in situ hybridization (FISH) with chromosome 8 centromere (CEP8) probe were used to identify CTCs. Cells with features of CD45-/DAPI+/CEP8>2 were detected as CTCs. Results: CTCs were classified as triploid, tetraploid and multiploid based on chromosome 8 copy number. CTC subtype composition was significantly different among groups. Both subtype number and total CTC number were significantly increased in PDAC patients, compared to healthy controls. Total CTC number had 75.8% sensitivity and 68.7% specificity at a cutoff value of 2 cells/3.2 mL. This study is the first to report that CTC subtype number is also useful in cancer diagnosis. Sensitivity was 53.7% and specificity was 85.4% at a cutoff point of 2 CTC subtypes. The diagnostic value of both total CTC number and CTC subtype number was a little poorer than CA199. Conclusions: Both CTC subtype and total CTC number may serve as potential biomarkers for PDAC.

show abstract

Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis

Cited by 58 publications

References 52 publications

Performance of different biomarkers for the management of hepatocellular carcinoma

Performance of different biomarkers for the management of hepatocellular carcinoma

An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma

Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About